The Latin America, Middle East and Africa Inhalation Anesthesia Market is expected to witness market growth of 10.7% CAGR during the forecast period (2022-2028).
In the operating room, inhalation anesthetics (nitrous oxide, isoflurane, halothane, sevoflurane, and desflurane are the most often used agents today) are used to induce and maintain general anesthesia. The volatile anesthetics (halothane, isoflurane, desflurane, and sevoflurane) are liquids at room temperature and must be administered using vaporizers. Under normal temperature and pressure, nitrous oxide is already present. Except for nitrous oxide, which also delivers analgesia, all inhalational anesthetics cause amnesia and immobility. Inhaled anesthetics are frequently used in conjunction with intravenous anesthetics. These drugs have been approved by the FDA for use in the operating room as general anesthetic and sedative agents.
The United Arab Emirates spends 4.28 percent of its budget on healthcare. The UAE government has made building a world-class healthcare infrastructure a primary priority, and as a result, the industry has grown and expanded tremendously in recent years. According to the World Health Organization, one-third of adults in the UAE are obese, and one out of every five persons has diabetes. As the prevalence of lifestyle diseases rises, these people will require higher-quality healthcare, owing to their relatively high-income levels. The government is concentrating its efforts on building a healthcare infrastructure to meet this demand.
Both the federal and emirate levels of government oversee healthcare in the UAE. Federal legislation stems from the 1970s and 1980s, and there are currently pending legislative reform proposals to help the healthcare business develop. The UAE government is liberalizing rules in order to attract international investment and raise the standard of healthcare in the country.
The Brazil market dominated the LAMEA Inhalation Anesthesia Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $33.7 Million by 2028. The Argentina market is poised to grow at a CAGR of 11.3% during (2022-2028). Additionally, The UAE market is expected to display a CAGR of 10.4% during (2022-2028).
Based on Drug, the market is segmented into Sevoflurane, Desflurane, Isoflurane, and Others. Based on Application, the market is segmented into Maintenance and Induction. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Piramal Enterprises Limited, Hikma Pharmaceuticals PLC, Fresenius SE & Co. KGaA, Baxter International, Inc., AbbVie, Inc., Halocarbon Products Corporation, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Lunan Pharmaceutical Group Co., Ltd., and Troikaa Pharmaceuticals Limited.
By Drug
In the operating room, inhalation anesthetics (nitrous oxide, isoflurane, halothane, sevoflurane, and desflurane are the most often used agents today) are used to induce and maintain general anesthesia. The volatile anesthetics (halothane, isoflurane, desflurane, and sevoflurane) are liquids at room temperature and must be administered using vaporizers. Under normal temperature and pressure, nitrous oxide is already present. Except for nitrous oxide, which also delivers analgesia, all inhalational anesthetics cause amnesia and immobility. Inhaled anesthetics are frequently used in conjunction with intravenous anesthetics. These drugs have been approved by the FDA for use in the operating room as general anesthetic and sedative agents.
The United Arab Emirates spends 4.28 percent of its budget on healthcare. The UAE government has made building a world-class healthcare infrastructure a primary priority, and as a result, the industry has grown and expanded tremendously in recent years. According to the World Health Organization, one-third of adults in the UAE are obese, and one out of every five persons has diabetes. As the prevalence of lifestyle diseases rises, these people will require higher-quality healthcare, owing to their relatively high-income levels. The government is concentrating its efforts on building a healthcare infrastructure to meet this demand.
Both the federal and emirate levels of government oversee healthcare in the UAE. Federal legislation stems from the 1970s and 1980s, and there are currently pending legislative reform proposals to help the healthcare business develop. The UAE government is liberalizing rules in order to attract international investment and raise the standard of healthcare in the country.
The Brazil market dominated the LAMEA Inhalation Anesthesia Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $33.7 Million by 2028. The Argentina market is poised to grow at a CAGR of 11.3% during (2022-2028). Additionally, The UAE market is expected to display a CAGR of 10.4% during (2022-2028).
Based on Drug, the market is segmented into Sevoflurane, Desflurane, Isoflurane, and Others. Based on Application, the market is segmented into Maintenance and Induction. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Piramal Enterprises Limited, Hikma Pharmaceuticals PLC, Fresenius SE & Co. KGaA, Baxter International, Inc., AbbVie, Inc., Halocarbon Products Corporation, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Lunan Pharmaceutical Group Co., Ltd., and Troikaa Pharmaceuticals Limited.
Scope of the Study
Market Segments Covered in the Report:
By Drug
- Sevoflurane
- Desflurane
- Isoflurane
- Others
- Maintenance
- Induction
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Novartis AG
- Piramal Enterprises Limited
- Hikma Pharmaceuticals PLC
- Fresenius SE & Co. KGaA
- Baxter International, Inc.
- AbbVie, Inc.
- Halocarbon Products Corporation
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Lunan Pharmaceutical Group Co., Ltd.
- Troikaa Pharmaceuticals Limited
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. LAMEA Inhalation Anesthesia Market by Drug
Chapter 4. LAMEA Inhalation Anesthesia Market by Application
Chapter 5. LAMEA Inhalation Anesthesia Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Novartis AG
- Piramal Enterprises Limited
- Hikma Pharmaceuticals PLC
- Fresenius SE & Co. KGaA
- Baxter International, Inc.
- AbbVie, Inc.
- Halocarbon Products Corporation
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Lunan Pharmaceutical Group Co., Ltd.
- Troikaa Pharmaceuticals Limited
Methodology
LOADING...
